Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers

Oncol Rep. 1998 Jul-Aug;5(4):871-4. doi: 10.3892/or.5.4.871.

Abstract

The significance of serum p53-Abs in patients with esophageal squamous cell carcinoma was determined. Examination of clinicopathological features and assessment of tumor marker sensitivities of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag) and CYFRA21-1 were performed. Thirty-three (58%) of 57 patients were positive for serum p53-Abs, however, no relation with cancer progression existed. Fourteen of the 33 sero-positive patients revealed normal levels of all tumor markers tested. Thus, serum p53-Abs appears to be a useful marker for the detection of esophageal squamous cell carcinoma.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies / blood*
  • Antigens, Neoplasm / blood
  • Biomarkers, Tumor / blood*
  • Carcinoembryonic Antigen / blood
  • Carcinoma, Squamous Cell / immunology*
  • Carcinoma, Squamous Cell / pathology
  • Esophageal Neoplasms / immunology*
  • Esophageal Neoplasms / pathology
  • Female
  • Genes, p53*
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Sensitivity and Specificity
  • Serpins*
  • Tumor Suppressor Protein p53 / immunology*

Substances

  • Antibodies
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Serpins
  • Tumor Suppressor Protein p53
  • squamous cell carcinoma-related antigen